Johns Hopkins Diabetes Guide
Afrezza
INDICATIONS
FDA
FDA
- Approved for use as a rapid-acting insulin to be given at the start of meals in adult patients with diabetes mellitus
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: June 2, 2019
Citation
Patel, Nisha K, et al. "Afrezza." Johns Hopkins Diabetes Guide, 2019. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547195/all/Afrezza.
Patel NK, Emiliano A, Pinto B. Afrezza. Johns Hopkins Diabetes Guide. 2019. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547195/all/Afrezza. Accessed June 1, 2023.
Patel, N. K., Emiliano, A., & Pinto, B. (2019). Afrezza. In Johns Hopkins Diabetes Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547195/all/Afrezza
Patel NK, Emiliano A, Pinto B. Afrezza [Internet]. In: Johns Hopkins Diabetes Guide. ; 2019. [cited 2023 June 01]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547195/all/Afrezza.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Afrezza
ID - 547195
A1 - Patel,Nisha,Pharm.D.
AU - Emiliano,Ana,M.D.
AU - Pinto,Brian,Pharm.D.
Y1 - 2019/06/02/
BT - Johns Hopkins Diabetes Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547195/all/Afrezza
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
